2018 American Transplant Congress
Comparing Outcomes between Induction Immunosuppressive Therapies in Simultaneous Heart/Kidney Transplantation
Virginia Commonwealth University, Richmond.
Introduction: There is no published data on the risks and benefits of Induction immunosuppression in simultaneous heart/kidney transplant (SHKT) patients.Methods: We analyzed all SHKT performed…2018 American Transplant Congress
Prevalence and Impact of CYP3A5 Genomic Variances on Clinical Outcomes among African-American Kidney Transplant Recipients
1Vidant Medical Center, Greenville, NC; 2East Carolina University, Greenville, NC.
Introduction: Kidney transplantation in African American (AA) recipients continues to demonstrate inferior outcomes when compared with other race/ethnicities. Contributing factors encompass differences in pharmacogenomics, and…2018 American Transplant Congress
TGR5-Mediated AMPK/mTOR Signaling Regulates Macrophage Migration and Polarization in Liver Ischemia Reperfusion
Background: Although the plasma membrane-bound G protein–coupled bile acid receptor (TGR5) exerts protective roles in various inflammatory diseases, little is known about the effects and…2018 American Transplant Congress
Racial Differences in Rates of Malignant and Infectious Cutaneous Genital Disease after Solid Organ Transplantation
Purpose: To describe the prevalence and types of genital lesions observed in OTRsMethods: This retrospective review included 496 OTRs who underwent full skin examination at…2018 American Transplant Congress
Post-Hoc Analysis of Everolimus Trough Levels around the Onset of Related Adverse Events and Treatment Discontinuation in De Novo Kidney Transplant Recipients from the US92 Study
1US92 Study Group, Salt Lake City; 2Novartis Pharmaceutical Corporation, East Hanover.
Purpose: Around 30%-50% of kidney transplant recipients (KTR) on sirolimus discontinue treatment due to drug-related adverse events (AE) and ~23% on everolimus (EVR) discontinue treatment…2018 American Transplant Congress
Long-Term Efficacy and Safety of Prolonged-Release Tacrolimus in Stable Pediatric Allograft Recipients Converted from Immediate-Release Tacrolimus
Study assessed long-term efficacy/safety of prolonged-release tacrolimus (PR-T) in stable solid organ allograft recipients (aged 5–16 yrs) who participated in a multicenter, Phase II pharmacokinetics…2018 American Transplant Congress
Identification of Novel Genetic Variants Associated with Tacrolimus Metabolism in Kidney Transplant Recipients Using Next Generation Sequencing
Tacrolimus (Tac) pharmacogenomics studies have identified common genetic variants that alter Tac troughs and developed specific dosing strategies for specific populations. Known common variants and…2018 American Transplant Congress
Presence of Chronic Vascular Lesions on Allograft Biopsy is Associated with Greater Improvement in Renal Function after Conversion from Tacrolimus to Belatacept
Background: Conversion from tacrolimus to belatacept has been shown to be beneficial for an increasing number of kidney transplant (KT) patients. However, predicting factors for…2018 American Transplant Congress
Pharmacokinetics of Mycophenolic Acid Following Enteric-Coated Mycophenolate Sodium Administration in Chinese Renal Transplant Recipients
MyERA Study Group, Hangzhou, China.
Background: Mycophenolic acid (MPA), active component of mycophenolate mofetil (MMF) or enteric-coated mycophenolate sodium (EC-MPS), is the most commonly used immunosuppressant in renal transplant recipients…2018 American Transplant Congress
Once-Daily Prolonged-Release Tacrolimus versus Twice-Daily Tacrolimus in Liver Transplantation: A Meta-Analysis
Background: A prolonged-release formulation of tacrolimus has been developed to provide once-daily dosing, with similar efficacy and safety to the standard twice-daily dosing and it…
- « Previous Page
- 1
- …
- 76
- 77
- 78
- 79
- 80
- …
- 138
- Next Page »